MYCL promotes the progression of triple-negative breast cancer by activating the JAK/STAT3 pathway

2Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

The present study aimed to investigate the underlying regulatory mechanism of MYCL proto-oncogene (MYCL) in triple-negative breast cancer (TNBC) progression. In vitro experiments were performed to confirm the functional roles of MYCL in TNBC, and its effects on the JAK/STAT3 pathway through flow cytometric analysis, colony formation, wound healing and Transwell assays. In addition, the GSE45498 dataset demonstrated that MYCL was upregulated in TNBC and that it was significantly related to poor survival of patients with TNBC. Knockdown of MYCL induced the apoptosis, and suppressed the proliferation, migration and invasion of TNBC cells by inhibiting the JAK/STAT3 pathway. Notably, MYCL could activate the JAK/STAT3 pathway, whereas inhibition of the JAK/STAT3 pathway could eliminate the effect of MYCL on TNBC cells. Knockdown of MYCL also suppressed the growth of TNBC xenograft tumors. In conclusion, MYCL could promote TNBC progression by activating the JAK/STAT3 pathway.

Cite

CITATION STYLE

APA

Jiang, H., Li, X., Wang, W., Hu, Y., & Ren, D. (2022). MYCL promotes the progression of triple-negative breast cancer by activating the JAK/STAT3 pathway. Oncology Reports, 48(5). https://doi.org/10.3892/or.2022.8418

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free